Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40


KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia.

Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, de Fontbrune FS, de Latour RP, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M.

Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322. [Epub ahead of print]


KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.

Battistella M, Leboeuf C, Ram-Wolff C, Hurabielle C, Bonnafous C, Sicard H, Bensussan A, Bagot M, Janin A.

Blood. 2017 Dec 28;130(26):2900-2902. doi: 10.1182/blood-2017-06-792382. Epub 2017 Oct 31. No abstract available.


Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.

Hurabielle C, Thonnart N, Ram-Wolff C, Sicard H, Bensussan A, Bagot M, Marie-Cardine A.

Clin Cancer Res. 2017 Jul 15;23(14):3619-3627. doi: 10.1158/1078-0432.CCR-16-3185. Epub 2017 Jan 24.


CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Benoit BM, Jariwala N, O'Connor G, Oetjen LK, Whelan TM, Werth A, Troxel AB, Sicard H, Zhu L, Miller C, Takeshita J, McVicar DW, Kim BS, Rook AH, Wysocka M.

Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.


KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L.

Br J Dermatol. 2016 Aug;175(2):325-33. doi: 10.1111/bjd.14626. Epub 2016 Jul 13.


A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A.

Oncoimmunology. 2015 Jun 1;4(9):e1022306. eCollection 2015 Sep.


The PPARα pathway in Vγ9Vδ2 T cell anergy.

Poupot M, Boissard F, Betous D, Bardouillet L, Fruchon S, L'Faqihi-Olive F, Pont F, Mekaouche M, Ingoure S, Sicard H, Dubreuilh G, Fournié JJ.

Cell Mol Biol Lett. 2014 Dec;19(4):649-58. doi: 10.2478/s11658-014-0218-0. Epub 2014 Nov 25.


IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.

Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C, Bensussan A, Bagot M, Sicard H.

Cancer Res. 2014 Nov 1;74(21):6060-70. doi: 10.1158/0008-5472.CAN-14-1456.


Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.

Sako N, Schiavon V, Bounfour T, Dessirier V, Ortonne N, Olive D, Ram-Wolff C, Michel L, Sicard H, Marie-Cardine A, Bagot M, Bensussan A, Schmitt C.

Cytometry A. 2014 Oct;85(10):869-82. doi: 10.1002/cyto.a.22512. Epub 2014 Jul 18.


In vivo manipulation of γ9(+) T cells in the common marmoset (Callithrix Jacchus) with phosphoantigen and effect on the progression of respiratory melioidosis.

Laws TR, Nelson M, Bonnafous C, Sicard H, Taylor C, Salguero FJ, Atkins TP, Oyston PC, Rowland CA.

PLoS One. 2013 Sep 30;8(9):e74789. doi: 10.1371/journal.pone.0074789. eCollection 2013.


Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates.

Chen CY, Yao S, Huang D, Wei H, Sicard H, Zeng G, Jomaa H, Larsen MH, Jacobs WR Jr, Wang R, Letvin N, Shen Y, Qiu L, Shen L, Chen ZW.

PLoS Pathog. 2013 Aug;9(8):e1003501. doi: 10.1371/journal.ppat.1003501. Epub 2013 Aug 15.


In vivo interferon-alpha/ribavirin treatment modulates Vγ9Vδ2 T-cell function during chronic HCV infection.

Cimini E, Bonnafous C, Sicard H, Vlassi C, D'Offizi G, Capobianchi MR, Martini F, Agrati C.

J Interferon Cytokine Res. 2013 Mar;33(3):136-41. doi: 10.1089/jir.2012.0050. Epub 2013 Jan 11.


What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G.

Cell Mol Immunol. 2013 Jan;10(1):35-41. doi: 10.1038/cmi.2012.39. Epub 2012 Dec 17. Review.


Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection.

Cimini E, Bonnafous C, Bordoni V, Lalle E, Sicard H, Sacchi A, Berno G, Gioia C, D'Offizi G, Visco Comandini U, Vlassi C, Capobianchi MR, Martini F, Agrati C.

PLoS One. 2012;7(5):e37014. doi: 10.1371/journal.pone.0037014. Epub 2012 May 22.


Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors.

Bennouna J, Levy V, Sicard H, Senellart H, Audrain M, Hiret S, Rolland F, Bruzzoni-Giovanelli H, Rimbert M, Galéa C, Tiollier J, Calvo F.

Cancer Immunol Immunother. 2010 Oct;59(10):1521-30. doi: 10.1007/s00262-010-0879-0. Epub 2010 Jun 19.


gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.

Braza MS, Caraux A, Rousset T, Lafaye de Micheaux S, Sicard H, Squiban P, Costes V, Klein B, Rossi JF.

J Immunol. 2010 Jan 1;184(1):134-40. doi: 10.4049/jimmunol.0901980. Epub 2009 Nov 30.


Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR gamma/delta+ T cell isolation kit".

Salot S, Bercegeay S, Dreno B, Saïagh S, Scaglione V, Bonnafous C, Sicard H.

J Immunol Methods. 2009 Aug 15;347(1-2):12-8. doi: 10.1016/j.jim.2009.05.006. Epub 2009 May 22.


Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.

Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ.

Blood. 2009 May 14;113(20):4875-84. doi: 10.1182/blood-2008-08-172296. Epub 2009 Mar 10.


Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection.

Gong G, Shao L, Wang Y, Chen CY, Huang D, Yao S, Zhan X, Sicard H, Wang R, Chen ZW.

Blood. 2009 Jan 22;113(4):837-45. doi: 10.1182/blood-2008-06-162792. Epub 2008 Nov 3.


Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate.

Boëdec A, Sicard H, Dessolin J, Herbette G, Ingoure S, Raymond C, Belmant C, Kraus JL.

J Med Chem. 2008 Mar 27;51(6):1747-54. doi: 10.1021/jm701101g. Epub 2008 Feb 28.


A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct gammadelta and alphabeta T cell responses in primates.

Cendron D, Ingoure S, Martino A, Casetti R, Horand F, Romagné F, Sicard H, Fournié JJ, Poccia F.

Eur J Immunol. 2007 Feb;37(2):549-65.


Standardization of an ash (Fraxinus excelsior) pollen allergen extract.

Hrabina M, Purohit A, Oster JP, Papanikolaou I, Jain K, Pascal P, Sicard H, Gouyon B, Moingeon P, Pauli G, André C.

Int Arch Allergy Immunol. 2007;142(1):11-8. Epub 2006 Sep 29.


In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.

Sicard H, Ingoure S, Luciani B, Serraz C, Fournié JJ, Bonneville M, Tiollier J, Romagné F.

J Immunol. 2005 Oct 15;175(8):5471-80.


Diagnosis of cypress pollen allergy: in vivo and in vitro standardization of a Juniperus ashei pollen extract.

Hrabina M, Dumur JP, Sicard H, Viatte A, Andre C.

Allergy. 2003 Aug;58(8):808-13.


[Conjunctival provocation test with Dermatophagoides pteronyssinus in the diagnosis of allergic conjunctivitis from house mites].

Bertel F, Mortemousque B, Sicard H, André C.

J Fr Ophtalmol. 2001 Jun;24(6):581-9. French.


Y2K+1 state-of-the-art on non-peptide phosphoantigens, a novel category of immunostimulatory molecules.

Espinosa E, Belmant C, Sicard H, Poupot R, Bonneville M, Fournié JJ.

Microbes Infect. 2001 Jul;3(8):645-54. Review.


A chemical basis for selective recognition of nonpeptide antigens by human delta T cells.

Belmant C, Espinosa E, Halary F, Tang Y, Peyrat MA, Sicard H, Kozikowski A, Buelow R, Poupot R, Bonneville M, Fournié JJ.

FASEB J. 2000 Sep;14(12):1669-70. No abstract available. Erratum in: FASEB J 2000 Oct;14(13):2128.


Metabolic routes as targets for immunological discrimination of host and parasite.

Sicard H, Fournie JJ.

Infect Immun. 2000 Aug;68(8):4375-7. Review. No abstract available.


[Juniperus ashei: the gold standard of the Cuppressaceae].

André C, Dumur JP, Hrabina M, Lefebvre E, Sicard H.

Allerg Immunol (Paris). 2000 Mar;32(3):104-6. French.


Safety of sublingual-swallow immunotherapy in children and adults.

André C, Vatrinet C, Galvain S, Carat F, Sicard H.

Int Arch Allergy Immunol. 2000 Mar;121(3):229-34.


Conventional and non-conventional recognition of non-peptide antigens by T lymphocytes.

Belmant C, Espinosa E, Halary F, Apostolou I, Sicard H, Peyrat MA, Vercellone A, Kourilsky P, Gachelin G, Poupot R, Bonneville M, Fournié JJ.

C R Acad Sci III. 1999 Nov;322(11):919-24. Review. No abstract available.


Structure and functions of nucleolin.

Ginisty H, Sicard H, Roger B, Bouvet P.

J Cell Sci. 1999 Mar;112 ( Pt 6):761-72. Review.


Ultrastructural changes in the Schizosaccharomyces pombe nucleolus following the disruption of the gar2+ gene, which encodes a nucleolar protein structurally related to nucleolin.

Léger-Silvestre I, Gulli MP, Noaillac-Depeyre J, Faubladier M, Sicard H, Caizergues-Ferrer M, Gas N.

Chromosoma. 1997 Jun;105(7-8):542-52.


Mitosis-specific phosphorylation of gar2, a fission yeast nucleolar protein structurally related to nucleolin.

Gulli MP, Faubladier M, Sicard H, Caizergues-Ferrer M.

Chromosoma. 1997 Jun;105(7-8):532-41.


Latex allergy diagnosis: in vivo and in vitro standardization of a natural rubber latex extract.

Turjanmaa K, Palosuo T, Alenius H, Leynadier F, Autegarden JE, André C, Sicard H, Hrabina M, Tran TX.

Allergy. 1997 Jan;52(1):41-50.


[Standardization and systems of units for allergens. Reactivity index].

Hrabina M, Thao TX, André C, Garcelon M, Sicard H.

Allerg Immunol (Paris). 1995 May;27(5):142-4. French. No abstract available.


A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract.

Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H.

Allergy. 1994 May;49(5):309-13.


[Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].

Sabbah A, Lesellin J, Hassoun S, Sicard H, André C.

Allerg Immunol (Paris). 1993 Jun;25(6):241-7. French.


Supplemental Content

Loading ...
Support Center